Overview
Alveolar echinococcosis (AE) is a rare but serious parasitic disease caused by the larval stage of the tapeworm Echinococcus multilocularis. It is also known as alveolar hydatid disease or multilocular echinococcosis. Humans become infected accidentally by ingesting eggs of the parasite, typically through contact with infected foxes, dogs, or other definitive hosts, or by consuming contaminated food such as wild berries or vegetables. The disease is not inherited but acquired through environmental exposure. The parasite primarily affects the liver, where it forms tumor-like, infiltrative parasitic masses that grow slowly over years, often mimicking hepatic malignancy. The larval tissue proliferates by external budding, invading surrounding structures in a manner similar to a malignant tumor. If untreated, the disease can metastasize to distant organs including the lungs, brain, and bones. Key symptoms include upper abdominal pain, hepatomegaly, jaundice, weight loss, and fatigue. Because of its slow growth, the disease often has an asymptomatic incubation period of 5 to 15 years before clinical manifestation, and diagnosis is frequently made at an advanced stage. Treatment of alveolar echinococcosis requires a multidisciplinary approach. Radical surgical resection of the parasitic lesion, when feasible, remains the treatment of choice and offers the best chance of cure. Long-term antiparasitic therapy with benzimidazoles (primarily albendazole) is essential, both as adjunctive treatment following surgery and as the primary treatment for inoperable cases. Continuous albendazole therapy may be required for years or even lifelong in patients with non-resectable disease. Without treatment, the mortality rate is very high, exceeding 90% within 10 to 15 years of diagnosis. Early detection through screening programs in endemic areas and advances in imaging and serological diagnostics have improved outcomes. Liver transplantation may be considered in select cases with extensive hepatic involvement.
Also known as:
Clinical phenotype terms— hover any for plain English:
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Alveolar echinococcosis.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Alveolar echinococcosis.
Community
No community posts yet. Be the first to share your experience with Alveolar echinococcosis.
Start the conversation →Latest news about Alveolar echinococcosis
Disease timeline:
New recruiting trial: IM Bands in Inactive Hepatic CE
A new clinical trial is recruiting patients for Alveolar echinococcosis
New recruiting trial: Biliary Fistulas in Surgery of Liver Echinococcosis
A new clinical trial is recruiting patients for Alveolar echinococcosis
New recruiting trial: Presentation of Protoscolexes and Acephalocysts in the Fibrous Capsule Area of the Liver With Echinococcosis
A new clinical trial is recruiting patients for Alveolar echinococcosis
New recruiting trial: Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
A new clinical trial is recruiting patients for Alveolar echinococcosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Alveolar echinococcosis
What is Alveolar echinococcosis?
Alveolar echinococcosis (AE) is a rare but serious parasitic disease caused by the larval stage of the tapeworm Echinococcus multilocularis. It is also known as alveolar hydatid disease or multilocular echinococcosis. Humans become infected accidentally by ingesting eggs of the parasite, typically through contact with infected foxes, dogs, or other definitive hosts, or by consuming contaminated food such as wild berries or vegetables. The disease is not inherited but acquired through environmental exposure. The parasite primarily affects the liver, where it forms tumor-like, infiltrative para
At what age does Alveolar echinococcosis typically begin?
Typical onset of Alveolar echinococcosis is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Alveolar echinococcosis?
Yes — 1 recruiting clinical trial is currently listed for Alveolar echinococcosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Alveolar echinococcosis?
14 specialists and care centers treating Alveolar echinococcosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.